Mmm don't know about that Stock.
A liquidity event before human trials will certainly be more than 10c.....overwise PAB goes alone into clinical trials....no point selling to Pharma for under 10c at $190m valuation.
The opportunity for Pharma is unique here with PAB - the patents behind the unique MOA are gold....it's not like any other antibody tech.
Peer comparison against NASDAQ antibody companies is my guidepost for valuation.
The Yale connection, US based board directors and North American sub holders in top 10 tells me the valuations will be measured per NASDAQ metrics.
The lowest pre-clinical antibody deal size in the last 3 years was around AU$350m - off the top of my head. Most deals were between $1B and $6B.
Let's see what Pharma thinks when tox studies are complete and we're ready for the clinic.
I'm tipping +20c valuation min before clinic.
.
PAB chart, page-1663
- There are more pages in this discussion • 209 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAB (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.9¢ |
Change
-0.001(10.0%) |
Mkt cap ! $18.51M |
Open | High | Low | Value | Volume |
1.0¢ | 1.0¢ | 0.9¢ | $6.454K | 658.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
18 | 6367122 | 0.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.0¢ | 2855358 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
18 | 6367122 | 0.009 |
15 | 3463920 | 0.008 |
9 | 1796859 | 0.007 |
10 | 2754340 | 0.006 |
9 | 3244992 | 0.005 |
Price($) | Vol. | No. |
---|---|---|
0.010 | 2855358 | 5 |
0.011 | 1459625 | 3 |
0.012 | 1667407 | 6 |
0.013 | 990000 | 2 |
0.014 | 180000 | 1 |
Last trade - 14.14pm 28/03/2024 (20 minute delay) ? |
|
|||||
Last
0.9¢ |
  |
Change
-0.001 ( 10.0 %) |
|||
Open | High | Low | Volume | ||
1.0¢ | 1.0¢ | 0.9¢ | 2467579 | ||
Last updated 14.14pm 28/03/2024 ? |
Featured News
PAB (ASX) Chart |
The Watchlist
BGD
BARTON GOLD HOLDINGS LIMITED
Alex Scanlon, Managing Director & CEO
Alex Scanlon
Managing Director & CEO
SPONSORED BY The Market Online